	US 11,890,324 B2
	Compounds for use in inducing myocardial perfusion recovery
Anette Sams Nielsen, Kgs. Lyngby (DK); and Lars Ingvar Herbert Edvinsson, Lund (SE)
Assigned to Epoqe Pharma ApS, Copenhagen N (DK)
Appl. No. 17/309,720
Filed by Epoqe Pharma ApS, Copenhagen N (DK)
PCT Filed Dec. 20, 2019, PCT No. PCT/SE2019/051333 § 371(c)(1), (2) Date Jun. 16, 2021, PCT Pub. No. WO2020/130927, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 1851652-6 (SE), filed on Dec. 21, 2018.
Prior Publication US 2022/0031809 A1, Feb. 3, 2022
Int. Cl. A61K 38/00 (2006.01); A61P 9/08 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61K 38/22 (2006.01); A61K 45/06 (2006.01)

CPC A61K 38/225 (2013.01) [A61K 45/06 (2013.01); A61P 9/08 (2018.01)]

15 Claims

1. A method for the treatment of acute myocardial infarction (AMI), the method comprising:

administering a calcitonin gene-related peptide (CGRP) compound,

wherein the CGRP compound is N-alpha-[2-(2-{2-[(S)]-4-carboxy-4-(17-carboxyheptadecanoylamino)-butyryl-amino]-ethoxy}ethoxy)acetyl][Ser1]beta-human CGRP peptide (β-CGRP-analogue), and a pharmaceutically acceptable salts and solvates thereof,

wherein the CGRP compound is administered at least once per day, and

wherein the CGRP is administered for one to thirty consecutive days immediately after incident.